DOCSLIB.ORG

Localization and Function of Nk3 Subtype Tachykinin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Localization and Function of Nk3 Subtype Tachykinin Neuroscience 156 (2008) 987–994 LOCALIZATION AND FUNCTION OF3 SUBTYPENK TACHYKININ RECEPTORS OF LAYER V PYRAMIDAL NEURONS OF THE GUINEA-PIG MEDIAL PREFRONTAL CORTEX M. A. SIMMONS,a,b* C. D. SOBOTKA-BRINERa bral cortex. In layer V pyramidal neurons of the medial pre- a AND A. M. MEDD frontal cortex, activation of the3 receptor NK system plays an aDepartment of Neuroscience Biology, AstraZeneca Pharmaceuticals, excitatory role in modulating synaptic transmission. © 2008 Wilmington, DE 19850, USA IBRO. Published by Elsevier Ltd. All rights reserved. b Department of Integrative Medical Sciences, Northeastern Ohio UniKey- words: neurokinin B, autoradiography, receptor binding, versities College of Medicine, 4209 State Route 44, P.O. Box electrophysiology95, . Rootstown, OH 44272-0095, USA The tachykinins are a family of peptides that primarily act Abstract—The NK3 subtype of tachykinin receptor has been implicated as a modulator of synaptic transmission in severaas l neurotransmitters or neuromodulators in the CNS and brain regions, including the cerebral cortex. The localizatioperipheraln nervous system. The tachykinin family is de- and expression of 3 receptorsNK within the brain vary from fined characteristically by the conserved carboxy terminal species to species. In addition, the pharmacology3 of sequenceNK -Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is a receptor-specific antagonists shows significant species vari- variable amino acid. The endogenous mammalian tachy- ability. Among commonly used animal models, the pharma- kinins are substance P (SP), neurokinin A (NKA) and cology of the guinea-pigreceptor NK most closely resem- 3 neurokinin B (NKB) (Beaujouan et al., 2004). bles that of the human3 receptor. NK Here, we provide ana- tomical localization studies, receptor binding studies, and These endogenous peptides act preferentially at three tachykinin receptors, termed the NK ,NK and NK sub- studies of the electrophysiological effects 3 receptoof NKr 1 2 3 ligands of guinea-pig cortex using two commercially availtype- tachykinin receptors. The NK1 receptor exhibits a able ligands, the 3NK receptor peptide analog agonist senk- higher affinity for the binding of SP than for NKA or NKB tide, and the quinolinecarboxamide receptorNK antagonist 3 (Krause et al., 1994). The NK2 receptor binds NKA with the SB-222,200. highest affinity (Buck and Shatzer, 1998). For the NK3 Saturation binding studies with membranes isolated from receptor, the order of agonist potency is NKBϾNKAϾSP guinea-pig cerebral cortex showed saturable binding consis- tent with a single high affinity site. Autoradiographic studie(Laufers et al., 1986); however, all three ligands are capable revealed dense specific binding in layers II/III and layer ofV activatingof the receptor. Like adrenergic, opioid, taste the cerebral cortex. For electrophysiological studies, brain and other G-protein-coupled receptors, the deduced amino slices were prepared from prefrontal cortex of 3- to 14-dayacid- sequence of the tachykinin receptors is consistent old guinea pigs. Whole cell recordings were made fromwith laye ther seven transmembrane domain structure proposed ؉ V pyramidal neurons. In current clamp mode -con-with a K for this family of receptors. taining pipette solution, senktide depolarized the pyramidal The pharmacology of tachykinin receptors has been neurons and led to repetitive firing of action potentials. In voltage clamp mode with ؉-containinga Cs pipette solution, well characterized in pain, and the roles of tachykinin senktide application produced an inward current and a receptorcon- ligands in lacrimation, salivation, and smooth centration-dependent enhancement of the amplitude and thmusclee contraction have been well documented (Regoli et frequency of spontaneous excitatory postsynaptic poten- al., 1994). Only recently has evidence emerged regarding tials. The glutamatergic nature of these events was demontheir- role in psychopharmacology. Interest in the role of strated by block by glutamate receptor antagonists. TheNK ef-receptors in the brain has been piqued by the devel- fects of senktide were blocked by SB-222,200,recep an- NK 3 3 opment of the brain permeant, potent, NK -selective com- tor antagonist. 3 Taken together, these results are consistent with a funcpounds- osanetant (Kamali, 2001) and talnetant (Evange- lista, 2005). tional role for 3NK receptors located on neurons in the cere- Studies of the function and pharmacology of NK re- *Correspondence to: M. A. Simmons, Department of Integrative Med- 3 ical Sciences, Northeastern Ohio Universities College of Medicineceptors, have proven to be complicated in several respects. 4209 State Route 44, P.O. Box 95, Rootstown, OH 44272-0095,One USA. of the difficulties is that the distribution of NKB ex- Tel: ϩ1-330-325-6525; fax:ϩ1-330-325-5912. pressing neurons and of NK3 receptors in the brain varies E-mail address: [email protected] (M. A. Simmons). among commonly used animal models (Massi et al., 2000; Abbreviations: ACSF, artificial cerebrospinal fluid;AP5, D-(Ϫ)-2-amino- Langlois et al., 2001) and between some of these models 5-phosphonopentanoic acid;B max, maximal binding; EPSC, exci- tatory postsynaptic current;Kd, dissociation constant of the radioli- and primates (Nagano et al., 2006). The pharmacology of gand; K , inhibition constant; NBQX, 2,3-dioxo-6-nitro-1,2,3,4-tet- i small molecule antagonists also shows interspecies vari- rahydrobenzo[f]quinoxaline-7-sulfonamide; NKA, neurokinin A; NKB, ation. In general, tachykinin receptor antagonists show neurokinin B; NK3,NK3 subtype tachykinin receptor; RT, room tem- perature; SP, substance P. selectivity for either rat and mouse or guinea-pig and gerbil 0306-4522/08 © 2008 IBRO. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.neuroscience.2008.08.037 987 988 M. A. Simmons et al. / Neuroscience 156 (2008) 987–994 NK3 receptors (Chung et al., 1995; Emonds-Alt et al., radioligand. The reaction was allowed to equilibrate for 1.5 h at RT 2002; Sarau et al., 1997, 2000). The pharmacology of and harvested onto GF/B filter plates presoaked in 0.5% BSA. Filters were washed with cold wash buffer (0.02 M Tris–HCl, pH 7, these compounds at the human NK3 receptor is more accurately replicated in guinea-pig and gerbil models than 0.02% BSA), dried and counted on a Topcount instrument (Perkin Elmer, Waltham, MA, USA). For competition binding experiments, in rat and mouse (Regoli et al., 1994). compounds were dissolved in DMSO and serially diluted 1:3. Two Given the relative receptor distribution, pharmacology microliters of each compound concentration was transferred to a and potential utility of the guinea pig as an animal model, 96-well 500 ␮l polypropylene U-bottom plate for final assay con- ␮ 125 7 we have examined the localization and function of NK3 centrations in the range of 10 M to 0.17 pM. The [ I]-MePhe - receptors in the cerebral cortex of the guinea pig. Here, we NKB ligand was used at concentrations of 0.02–0.07 nM. The provide anatomical localization studies, ligand binding remainder of the assay was as described above. studies, and studies of the physiological effects of NK Saturation binding data were analyzed by non-linear regres- 3 sion using GraphPad Prism software to yield K (dissociation receptor activation and blockade. d constant of the radioligand) and Bmax (maximal binding). For competition binding experiments, inhibition constants (Ki) were calculated using the Cheng-Prusoff equation and XL-Fit software. EXPERIMENTAL PROCEDURES Electrophysiology Animals Coronal slices were prepared from the frontal pole of the brain of Hartley guinea pigs (Charles River Laboratories, Wilmington, MA, guinea-pig neonates of either sex at 2–15 days of age, weighing USA) were used in these experiments. Animals were housed in a 40–200 g. Animals were decapitated after induction of deep an- temperature-controlled vivarium with free access to food and wa- esthesia with isoflurane. The brain was rapidly removed and im- ter. Animal experiments were approved by the AstraZeneca mersed in ice cold artificial cerebrospinal fluid (ACSF) gassed with IACUC and carried out in accordance with the National Institutes 95% O2–5% CO2. The brain was cut in half with a single coronal of Health Guide for the Care and Use of Laboratory Animals (NIH cut. The front half of the brain was mounted anterior side up in an Publications No. 80–23). The number of animals used and their ice cold gassed bath for slicing. Slices (200 ␮m) were cut using a suffering were minimized. Vibratome (Leica Microsystems). The first four slices were dis- carded. Subsequent slices were stored in a warm (30 °C) holding chamber gassed with 95% O2–5% CO2. Slices were allowed to Autoradiography equilibrate for at least 1 h before recording. Individual slices were transferred to a recording chamber which was perfused with Naïve adult male Hartley guinea pigs were killed by decapitation gassed ACSF at 2.0 ml/min. Whole cell recordings of single neu- without anesthesia. Brains were removed and frozen in cooled rons were conducted at RT, ϳ23 °C, using an Axopatch 200C isopentane (Ϫ35 °C). Sections (20 ␮m) were cut in a cryostat at (Hamden, CT, USA) patch clamp amplifier. Electrodes with resis- Ϫ15 °C, mounted onto gelatin-coated slides, rapidly dried and tances of 4–8 M⍀ were filled with pipette solution. Drugs were stored at Ϫ80 °C until use. On the day of the experiment, slides applied by bath perfusion. were warmed to room temperature (RT, ϳ22–25 °C) and prein- The composition of solutions used for these experiments is cubated in 50 mM Tris–HCl, 0.005% polyethylamine, pH 7.4. To determine total binding the sections were incubated in the same listed below, in mM unless stated otherwise. ACSF: 130 NaCl, 3.5 3 KCl, 1.5 CaCl2, 1.5 MgSO4, 24 NaHCO3, 1.25 NaH2PO4,10 buffer with 3 mM MnCl2, 0.02% BSA, and 1 nM [ H] SB-222,200 (in house, specific activity 34.7 Ci/mmol) for 60 min.
Load more

Recommended publications
  • Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
    REVIEW ARTICLE published: 01 February 2013 doi: 10.3389/fphar.2013.00007 Drug development for the irritable bowel syndrome: current challenges and future perspectives Fabrizio De Ponti* Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Edited by: Medications are frequently used for the treatment of patients with the irritable bowel syn- Angelo A. Izzo, University of Naples drome (IBS), although their actual benefit is often debated. In fact, the recent progress in Federico II, Italy our understanding of the pathophysiology of IBS, accompanied by a large number of preclin- Reviewed by: Elisabetta Barocelli, University of ical and clinical studies of new drugs, has not been matched by a significant improvement Parma, Italy of the armamentarium of medications available to treat IBS. The aim of this review is to Raffaele Capasso, University of outline the current challenges in drug development for IBS, taking advantage of what we Naples Federico II, Italy have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions *Correspondence: that will be addressed are: (a) do we still believe in the “magic bullet,” i.e., a very selective Fabrizio De Ponti, Pharmacology Unit, Department of Medical and Surgical drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS Sciences, University of Bologna, Via is a “functional disorder” where complex neuroimmune and brain-gut interactions occur Irnerio, 48, 40126 Bologna, Italy. and minimal inflammation is often documented:
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • Tachykinins and Airway Microvascular Leakage Induced by Hcl Intra-Oesophageal Instillation
    Copyright #ERS Journals Ltd 2002 Eur Respir J 2002; 20: 268–273 European Respiratory Journal DOI: 10.1183/09031936.02.00250902 ISSN 0903-1936 Printed in UK – all rights reserved Tachykinins and airway microvascular leakage induced by HCl intra-oesophageal instillation S. Daoui*,B.D9Agostino#, L. Gallelli#, X. Emonds Alt}, F. Rossi#, C. Advenier* Tachykinins and airway microvascular leakage induced by HCl intra-oesophageal *Dept of Pharmacology, University instillation. S. Daoui, B. D9Agostino, L. Gallelli, X. Emonds Alt, F. Rossi, C. Advenier. Paris V, Paris, France, #Dept of #ERS Journals Ltd 2002. Experimental Medicine, Faculty of ABSTRACT: Gastro-oesophageal reflux is a common clinical disorder associated with Medicine and Surgery, Naples, Italy, }Sanofi Synthelabo Research, Montpel- a variety of respiratory symptoms, including chronic cough and exacerbation of asthma. lier, France. In this study, the potential role of acid-induced tachykinin release was examined in guinea pigs and rabbits, by examining the effects of the tachykinin NK1 and NK3 Correspondence: C. Advenier receptors antagonists (SR 140333 and SR 142801, respectively) (1–10 mg?kg-1)on Universite´ Paris V plasma protein extravasation induced in airways by hydrochloric acid (HCl) infusion in UPRES EA220, Pharmacologie the oesophagus. 45 rue des Saints Pe`res Guinea pigs were anaesthetised with urethane, while rabbits were subject to F-75006 Paris neuroleptoanalgesia with hypnorm. Airway vascular leakage was evaluated by France Fax: 33 142863810 measuring extravasation of Evans blue dye. All animals were pretreated with atropine E-mail: [email protected] (1 mg?kg-1 i.p.), propranolol (1 mg?kg-1 i.p.), phosphoramidon (2.5 mg?kg-1 i.v.) and -1 saline or tachykinin receptor antagonists (1–10 mg?kg i.p.).
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Selective Blockade of NK2 Or NK3 Receptors Produces Anxiolytic- and Antidepressant-Like Effects in Gerbils ⁎ N
    Pharmacology, Biochemistry and Behavior 83 (2006) 533–539 www.elsevier.com/locate/pharmbiochembeh Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils ⁎ N. Salomé, J. Stemmelin, C. Cohen , G. Griebel Sanofi-Aventis, Department of Psychopharmacology, 31 av Paul Vaillant-Couturier, 92220 Bagneux, France Received 17 October 2005; received in revised form 1 March 2006; accepted 9 March 2006 Available online 19 April 2006 Abstract There is a growing interest in the potential anxiolytic- and antidepressant-like effects of compounds that target neurokinin receptors. Since the structure and the pharmacology of the human neurokinin receptor resembles that of gerbils, rather than that of mice or rats, we decided to investigate the anxiolytic- and /or antidepressant-like effects of NK1 (SSR240600), NK2 (saredutant) and NK3 (osanetant) receptor antagonists in gerbils. It was found that saredutant (3–10 mg/kg, p.o.) and osanetant (3–10 mg/kg, p.o.) produced anxiolytic-like effects in the gerbil social interaction test. These effects were similar to those obtained with the V1b receptor antagonist SSR149415 (3–10 mg/kg, p.o.), diazepam (1 mg/kg, p.o.) and buspirone (10 mg/kg, p.o.). Fluoxetine and SSR240600 were devoid of effects in this test. In the tonic immobility test in gerbils, saredutant (5–10 mg/kg, i.p.) and osanetant (5–10 mg/kg, i.p.) produced similar effects to those observed with fluoxetine (7.5–15 mg/kg, i.p.), SSR149415 (10–30 mg/kg, p.o.) and buspirone (3 mg/kg, i.p.). Diazepam and SSR240600 were inactive in this paradigm.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Neurokinin Receptor NK Receptor
    Neurokinin Receptor NK receptor There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the Gαq-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP (cAMP) is stimulated by NK1R coupled to the Gαs-protein. The neurokinin receptors are expressed on many cell types and tissues. www.MedChemExpress.com 1 Neurokinin Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators Aprepitant Befetupitant (MK-0869; MK-869; L-754030) Cat. No.: HY-10052 (Ro67-5930) Cat. No.: HY-19670 Aprepitant (MK-0869) is a selective and Befetupitant is a high-affinity, nonpeptide, high-affinity neurokinin 1 receptor antagonist competitive tachykinin 1 receptor (NK1R) with a Kd of 86 pM. antagonist. Purity: 99.67% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg Size: 1 mg, 5 mg Biotin-Substance P Casopitant mesylate Cat. No.: HY-P2546 (GW679769B) Cat. No.: HY-14405A Biotin-Substance P is the biotin tagged Substance Casopitant mesylate (GW679769B) is a potent, P. Substance P (Neurokinin P) is a neuropeptide, selective, brain permeable and orally active acting as a neurotransmitter and as a neurokinin 1 (NK1) receptor antagonist.
    [Show full text]
  • Review Article
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2019, 70, 1, 15-24 www.jpp.krakow.pl | DOI: 10.26402/jpp.2019.1.01 Review article A. SZYMASZKIEWICZ 1, A. MALKIEWICZ 1, M. STORR 2,3 , J. FICHNA 1, M. ZIELINSKA 1 THE PLACE OF TACHYKININ NK2 RECEPTOR ANTAGONISTS IN THE TREATMENT DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME 1Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland; 2Department of Medicine, Division of Gastroenterology, Ludwig Maximilians University of Munich, Munich, Germany, 3Center of Endoscopy, Starnberg, Germany Tachykinins act as neurotransmitters and neuromodulators in the central and peripheral nervous system. Preclinical studies and clinical trials showed that inhibition of the tachykinin receptors, mainly NK2 may constitute a novel attractive option in the treatment of irritable bowel syndrome (IBS). In this review, we focused on the role of tachykinins in physiology and pathophysiology of gastrointestinal (GI) tract. Moreover, we summed up recent data on tachykinin receptor antagonists in the therapy of IBS. Ibodutant is a novel drug with an interesting pharmacological profile, which exerted efficacy in women with diarrhea-predominant IBS (IBS-D) in phase II clinical trials. The promising results were not replicable and confirmed in phase III of clinical trials. Ibodutant is not ready to be introduced in the pharmaceutical market and further studies on alternative NK2 antagonist are needed to make NK2 antagonists useful tools in IBS-D treatment. Key words: irritable bowel syndrome, abdominal pain, diarrhea, tachykinins, ibodutant, NK2 receptor antagonist, transient receptor potential vanilloid 1 channel INTRODUCTION drugs in IBS-D therapy is long and includes among others: agonists of opioid receptors, antidepressants, plant derived Irritable bowel syndrome (IBS) belongs to the group of drugs, antibiotics or serotonin 5-HT3 receptor antagonists etc .
    [Show full text]
  • Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects Of
    Gastroenterology 2016;150:1319–1331 Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders Michael Camilleri,1 Lionel Buéno,2,† Viola Andresen,3 Fabrizio De Ponti,4 Myung-Gyu Choi,5 and Anthony Lembo6 1Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota; 2INRA, Toulouse, France; 3Israelitic Hospital, University of Hamburg, Hamburg, Germany; 4Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 5Department of Gastroenterology, The Catholic University of Korea College of Medicine Internal Medicine, Seoul, Korea; and 6GI Motility Laboratory, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts This article reviews medications commonly used for the with a balloon connected to a barostat to measure simul- treatment of patients with functional gastrointestinal disor- taneously compliance and the response to gastrointestinal ders. Specifically, we review the animal models that have been distention. Balloons can be acutely or chronically implanted validated for the study of drug effects on sensation and in the gut.1 A number of factors influence reproducibility of motility; the preclinical pharmacology, pharmacokinetics, balloon distention studies across laboratories: balloon con- and toxicology usually required for introduction of new struction and unfolding, distention protocols, and frequency drugs; the biomarkers that are validated for studies of of balloon distentions in the same animal (which can lead to sensation and motility end points with experimental medica- sensitization), and species (eg, rats vs mice) or strain dif- tions in humans; the pharmacogenomics applied to these ferences within species. PHARMACOLOGY medications and their relevance to the FGIDs; and the phar- Chemical Stimuli. In rats, infusion of glycerol into the macology of agents that are applied or have potential for the colon through an implanted catheter induces abdominal treatment of FGIDs, including psychopharmacologic drugs.
    [Show full text]